Nifty
:
18338.55
Sensex
:
61305.95
176.80 (0.97%)
568.90 (0.94%)
Nifty
Sensex
:
:
18338.55
61305.95
176.80 (0.97%)
568.90 (0.94%)

Lupin Ltd.

Pharmaceuticals & Drugs - Global

Rating :
45/99

BSE: 500257 | NSE: LUPIN

NSE BSE
946.45
14-Oct-2021
  • Open
  • High
  • Low
  • Previous Close
  •  963.30
  •  968.15
  •  945.00
  •  963.30
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  938940
  •  8964.10
  •  1267.65
  •  855.35

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 42,955.82
  • 26.00
  • 2
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 45,996.34
  • 0.69%
  • 3.03

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 46.83%
  • 0.52%
  • 10.17%
  • FII
  • DII
  • Others
  • 15.66%
  • 24.51%
  • 2.31%

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 7.91
  • -2.82
  • -3.27

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 5.92
  • -10.59
  • -0.78

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 3.52
  • -13.61
  • 26.10

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 26.19
  • 23.17
  • -

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 4.84
  • 3.27
  • 3.04

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 16.18
  • 14.71
  • 15.47

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Jun 21
Jun 20
Var%
Mar 21
Mar 20
Var%
Dec 20
Dec 19
Var%
Sep 20
Sep 19
Var%
Net Sales
4,270.19
3,527.86
21.04%
3,783.10
3,845.74
-1.63%
4,017.36
3,769.27
6.58%
3,835.00
3,882.21
-1.22%
Expenses
3,342.62
3,039.78
9.96%
3,075.55
3,320.42
-7.37%
3,238.62
3,340.17
-3.04%
3,253.83
3,241.64
0.38%
EBITDA
927.57
488.08
90.04%
707.55
525.32
34.69%
778.74
429.10
81.48%
581.17
640.57
-9.27%
EBIDTM
21.72%
13.84%
18.70%
13.66%
19.38%
11.38%
15.15%
16.50%
Other Income
64.99
43.28
50.16%
58.22
208.60
-72.09%
21.17
93.59
-77.38%
24.96
127.96
-80.49%
Interest
33.47
44.26
-24.38%
31.84
107.38
-70.35%
30.92
88.60
-65.10%
33.62
82.59
-59.29%
Depreciation
208.76
214.64
-2.74%
215.72
214.26
0.68%
244.32
253.23
-3.52%
212.73
252.57
-15.77%
PBT
750.33
272.46
175.39%
518.21
495.37
4.61%
524.67
-107.82
-
359.78
-113.11
-
Tax
202.33
164.32
23.13%
54.01
105.07
-48.60%
83.49
767.02
-89.12%
146.70
69.52
111.02%
PAT
548.00
108.14
406.75%
464.20
390.30
18.93%
441.18
-874.84
-
213.08
-182.63
-
PATM
12.83%
3.07%
12.27%
10.15%
10.98%
-23.21%
5.56%
-4.70%
EPS
11.95
2.36
406.36%
10.15
8.60
18.02%
9.66
-18.44
-
4.66
-2.81
-

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Net Sales
15,905.65
15,162.96
16,836.56
16,751.37
15,804.15
17,494.33
14,139.03
12,770.01
11,286.57
9,641.30
7,082.91
Net Sales Growth
5.86%
-9.94%
0.51%
5.99%
-9.66%
23.73%
10.72%
13.14%
17.06%
36.12%
 
Cost Of Goods Sold
5,602.28
4,854.28
4,962.72
4,436.67
4,733.76
4,660.97
3,893.70
3,806.16
3,485.50
3,221.50
2,364.87
Gross Profit
10,303.37
10,308.68
11,873.84
12,314.70
11,070.39
12,833.36
10,245.33
8,963.85
7,801.07
6,419.80
4,718.04
GP Margin
64.78%
67.99%
70.52%
73.51%
70.05%
73.36%
72.46%
70.19%
69.12%
66.59%
66.61%
Total Expenditure
12,910.62
12,596.08
14,362.21
14,082.44
12,656.64
13,001.19
10,453.68
9,150.42
8,283.78
7,371.41
5,638.20
Power & Fuel Cost
-
414.48
443.17
442.28
433.88
377.86
381.27
362.81
334.29
320.22
268.82
% Of Sales
-
2.73%
2.63%
2.64%
2.75%
2.16%
2.70%
2.84%
2.96%
3.32%
3.80%
Employee Cost
-
2,825.90
2,986.84
2,770.17
2,864.71
2,849.52
2,141.62
1,747.34
1,464.65
1,266.62
969.53
% Of Sales
-
18.64%
17.74%
16.54%
18.13%
16.29%
15.15%
13.68%
12.98%
13.14%
13.69%
Manufacturing Exp.
-
1,945.67
1,852.21
1,731.57
2,087.52
2,270.19
1,766.00
1,320.55
1,129.59
976.51
753.07
% Of Sales
-
12.83%
11.00%
10.34%
13.21%
12.98%
12.49%
10.34%
10.01%
10.13%
10.63%
General & Admin Exp.
-
1,218.42
1,456.46
3,302.60
1,219.96
1,509.56
1,195.98
806.87
810.53
692.06
471.23
% Of Sales
-
8.04%
8.65%
19.72%
7.72%
8.63%
8.46%
6.32%
7.18%
7.18%
6.65%
Selling & Distn. Exp.
-
1,026.40
1,080.45
1,206.60
1,150.61
1,049.48
870.29
835.48
775.26
709.62
647.88
% Of Sales
-
6.77%
6.42%
7.20%
7.28%
6.00%
6.16%
6.54%
6.87%
7.36%
9.15%
Miscellaneous Exp.
-
310.93
1,580.36
192.55
166.20
283.61
204.82
271.21
283.96
184.88
647.88
% Of Sales
-
2.05%
9.39%
1.15%
1.05%
1.62%
1.45%
2.12%
2.52%
1.92%
2.30%
EBITDA
2,995.03
2,566.88
2,474.35
2,668.93
3,147.51
4,493.14
3,685.35
3,619.59
3,002.79
2,269.89
1,444.71
EBITDA Margin
18.83%
16.93%
14.70%
15.93%
19.92%
25.68%
26.07%
28.34%
26.60%
23.54%
20.40%
Other Income
169.34
136.29
483.76
333.01
150.35
106.51
185.19
239.75
116.48
27.85
14.35
Interest
129.85
140.64
362.98
302.49
204.35
152.53
59.47
9.81
26.65
40.95
35.47
Depreciation
881.53
887.41
970.22
846.05
1,085.87
912.23
487.13
434.70
260.97
332.19
227.52
PBT
2,152.99
1,675.12
1,624.91
1,853.40
2,007.64
3,534.89
3,323.94
3,414.83
2,831.65
1,924.60
1,196.07
Tax
486.53
448.52
1,146.56
901.69
288.46
978.51
1,059.34
970.40
962.15
584.16
308.56
Tax Rate
22.60%
26.78%
131.36%
59.58%
53.10%
27.68%
31.87%
28.42%
33.98%
30.35%
25.80%
PAT
1,666.46
1,226.60
-273.72
611.73
247.74
2,549.21
2,255.84
2,403.24
1,836.37
1,314.16
867.65
PAT before Minority Interest
1,651.16
1,226.60
-273.72
611.73
254.83
2,556.38
2,264.60
2,444.43
1,869.50
1,340.44
887.51
Minority Interest
-15.30
0.00
0.00
0.00
-7.09
-7.17
-8.76
-41.19
-33.13
-26.28
-19.86
PAT Margin
10.48%
8.09%
-1.63%
3.65%
1.57%
14.57%
15.95%
18.82%
16.27%
13.63%
12.25%
PAT Growth
398.10%
-
-
146.92%
-90.28%
13.00%
-6.13%
30.87%
39.74%
51.46%
 
EPS
36.71
27.02
-6.03
13.47
5.46
56.15
49.69
52.93
40.45
28.95
19.11

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Shareholder's Funds
13,803.14
12,536.70
13,742.23
13,577.06
13,497.57
11,163.37
8,874.06
6,931.57
5,204.18
4,012.89
Share Capital
90.74
90.60
90.50
90.42
90.32
90.12
89.90
89.68
89.51
89.33
Total Reserves
13,522.87
12,231.40
13,433.31
13,275.26
13,233.50
10,958.87
8,728.15
6,815.66
5,107.79
3,920.76
Non-Current Liabilities
1,136.03
3,003.18
7,296.41
6,876.13
6,446.96
6,032.39
426.15
507.16
572.87
729.96
Secured Loans
0.33
0.70
358.82
448.03
217.15
5.55
12.50
24.42
37.95
27.76
Unsecured Loans
15.79
1,792.58
6,282.90
5,976.47
5,430.63
5,368.35
89.33
126.54
209.11
405.20
Long Term Provisions
329.49
296.29
370.79
356.85
308.73
190.00
162.03
132.49
112.45
77.02
Current Liabilities
8,436.09
9,225.20
6,129.87
5,095.55
6,120.59
5,061.17
3,729.23
2,629.55
3,006.92
3,120.30
Trade Payables
2,014.44
2,412.30
2,498.18
2,575.40
2,588.90
1,988.82
1,956.06
1,594.13
1,542.88
1,379.28
Other Current Liabilities
2,451.01
3,124.23
1,279.82
1,517.16
657.97
1,001.27
829.76
287.64
381.25
377.17
Short Term Borrowings
3,049.44
2,492.75
1,580.21
451.76
2,304.33
1,745.41
369.15
402.38
726.82
1,046.99
Short Term Provisions
921.20
1,195.92
771.66
551.23
569.39
325.67
574.26
345.40
355.97
316.86
Total Liabilities
23,430.23
24,809.54
27,215.37
25,588.82
26,099.64
22,289.01
13,053.54
10,135.22
8,843.42
7,935.44
Net Block
7,880.76
7,938.11
11,086.71
10,361.99
11,032.93
8,716.96
4,368.19
3,355.60
3,000.17
2,749.66
Gross Block
14,726.75
14,160.50
15,731.88
13,859.86
12,395.30
9,212.07
6,644.59
5,283.90
4,684.21
4,191.84
Accumulated Depreciation
6,845.99
6,222.39
4,645.17
3,497.87
1,362.37
495.11
2,276.40
1,928.30
1,684.04
1,442.18
Non Current Assets
9,443.86
9,396.33
13,361.79
13,379.28
14,146.71
12,401.61
5,221.19
4,034.77
3,700.29
3,593.12
Capital Work in Progress
1,066.26
939.62
1,639.71
2,598.20
2,133.06
2,702.40
551.87
285.90
310.70
434.84
Non Current Investment
78.07
36.07
185.63
26.71
22.00
14.33
2.51
2.06
2.06
2.80
Long Term Loans & Adv.
405.79
409.58
402.61
383.00
950.76
960.22
274.20
372.99
387.36
396.94
Other Non Current Assets
12.98
72.95
47.13
9.38
7.96
7.70
0.32
0.00
0.00
0.00
Current Assets
13,986.37
15,413.21
13,853.58
12,209.54
11,952.93
9,887.40
7,832.35
6,100.45
5,143.13
4,342.32
Current Investments
2,376.81
2,338.25
2,109.86
234.86
2,114.13
2.02
1,655.89
176.41
0.00
0.00
Inventories
4,092.01
3,456.87
3,836.77
3,662.49
3,642.28
3,273.65
2,503.56
2,129.45
1,948.93
1,732.67
Sundry Debtors
4,474.32
5,445.93
5,149.80
5,192.21
4,307.34
4,548.76
2,656.57
2,464.10
2,186.99
1,780.01
Cash & Bank
1,742.46
2,454.30
987.20
1,408.03
698.17
821.75
481.35
797.50
434.88
402.47
Other Current Assets
1,300.77
537.33
777.47
621.30
1,191.01
1,241.22
534.98
532.99
572.33
427.17
Short Term Loans & Adv.
743.88
1,180.53
992.48
1,090.65
657.58
761.78
294.91
275.15
339.67
306.12
Net Current Assets
5,550.28
6,188.01
7,723.71
7,113.99
5,832.34
4,826.23
4,103.12
3,470.90
2,136.21
1,222.02
Total Assets
23,430.23
24,809.54
27,215.37
25,588.82
26,099.64
22,289.01
13,053.54
10,135.22
8,843.42
7,935.44

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Cash From Operating Activity
1,821.76
1,468.84
1,665.97
1,751.19
4,113.51
-382.39
2,733.05
2,003.93
1,250.96
560.04
PBT
1,676.45
876.78
1,517.17
546.81
3,543.14
3,328.84
3,414.83
2,831.65
1,924.60
1,196.07
Adjustment
1,053.31
1,574.29
1,588.41
2,782.23
1,214.74
585.35
356.73
410.50
419.58
258.51
Changes in Working Capital
-192.49
-471.02
-500.19
-1,019.43
504.62
-3,126.44
-94.91
-466.31
-549.35
-580.65
Cash after chg. in Working capital
2,537.27
1,980.05
2,605.39
2,309.61
5,262.50
787.75
3,676.65
2,775.84
1,794.83
873.93
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-715.51
-511.21
-939.42
-558.42
-1,148.99
-1,170.14
-943.60
-771.91
-543.87
-313.89
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
-1,239.58
1,106.99
-3,282.47
469.87
-2,527.44
-6,961.71
-1,054.51
-858.54
-521.86
-741.25
Net Fixed Assets
-693.00
-481.49
-462.56
-1,394.31
-876.24
480.96
-416.45
-309.36
-324.79
-389.71
Net Investments
-2,106.15
-67.96
-2,025.62
1,551.07
-3,173.10
-296.59
-2,280.57
-475.62
-0.75
-6.41
Others
1,559.57
1,656.44
-794.29
313.11
1,521.90
-7,146.08
1,642.51
-73.56
-196.32
-345.13
Cash from Financing Activity
-1,885.27
-890.58
744.13
-1,492.10
433.18
5,836.38
-196.89
-857.11
-662.82
108.86
Net Cash Inflow / Outflow
-1,303.09
1,685.25
-872.37
728.96
2,019.25
-1,507.72
1,481.65
288.28
66.28
-72.35
Opening Cash & Equivalents
2,229.31
544.06
1,416.43
687.47
780.22
2,095.06
606.62
310.93
244.65
295.88
Closing Cash & Equivalent
926.22
2,229.31
544.06
1,416.43
2,799.47
780.22
2,108.43
606.62
310.93
244.65

Financial Ratios

Consolidated /

Standalone
Description
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Book Value (Rs.)
300.06
272.01
298.87
295.64
295.04
245.21
196.17
154.00
116.13
89.78
ROA
5.09%
-1.05%
2.32%
0.99%
10.57%
12.82%
21.08%
19.70%
15.98%
12.40%
ROE
9.46%
-2.12%
4.55%
1.91%
20.98%
22.80%
31.09%
30.89%
29.12%
24.35%
ROCE
9.70%
6.02%
8.45%
3.54%
18.53%
24.38%
40.30%
40.97%
32.70%
24.40%
Fixed Asset Turnover
1.96
2.10
1.93
2.07
1.63
1.80
2.16
2.28
2.19
1.99
Receivable days
64.06
61.62
66.11
63.76
91.82
92.24
72.65
74.67
74.61
77.76
Inventory Days
48.75
42.41
47.94
49.03
71.70
73.96
65.73
65.48
69.24
75.12
Payable days
62.54
65.89
68.49
68.56
60.60
63.20
64.43
63.78
63.76
64.11
Cash Conversion Cycle
50.26
38.14
45.56
44.23
102.92
103.00
73.94
76.37
80.10
88.76
Total Debt/Equity
0.35
0.51
0.63
0.53
0.60
0.65
0.06
0.09
0.22
0.41
Interest Cover
12.91
3.40
6.00
3.66
24.18
56.89
349.10
107.25
48.00
34.72

Annual Reports:

FY 2021
FY 2020
FY 2019
FY 2018
FY 2017
FY 2016
FY 2015
FY 2014
FY 2013
FY 2012

News Update:


  • Lupin receives tentative approval from USFDA for Brexpiprazole Tablets
    7th Oct 2021, 09:16 AM

    This product will be manufactured at Lupin's Pithampur facility In India

    Read More
  • USFDA concludes inspection at Lupin’s Goa facility
    20th Sep 2021, 09:30 AM

    The inspection was carried out from September 6, 2021 to September 18, 2021 and closed with seven observations

    Read More
  • Lupin launches authorized generic version of Duexis in United States
    15th Sep 2021, 15:31 PM

    Ibuprofen and Famotidine Tablets, 800 mg/26.6 mg, are indicated for the relief of signs and symptoms of rheumatoid arthritis, osteoarthritis

    Read More
  • Lupin gets non-exclusive license from TB Alliance to manufacture anti-TB drug pretomanid
    6th Sep 2021, 11:19 AM

    The company intends to commercialize the antituberculosis (TB) medicine in approximately 140 countries and territories

    Read More
  • Lupin launches Luforbec 100/6 dose
    24th Aug 2021, 16:24 PM

    Luforbec is indicated for the treatment of adult asthma and for the symptomatic treatment of severe chronic obstructive pulmonary disease

    Read More
  • Lupin gets USFDA’s tentative approval for Brivaracetam Tablets
    17th Aug 2021, 09:12 AM

    Brivaracetam Tablets had estimated annual sales of $311 million in the U.S

    Read More
  • Lupin reports 5- fold jump in Q1 consolidated net profit
    11th Aug 2021, 10:57 AM

    Total income of the company increased by 20.35% at Rs 4298.02 crore for Q1FY22

    Read More
  • Lupin’s arm to acquire 100% stake in Southern Cross Pharma Pty
    30th Jul 2021, 11:19 AM

    As a part of the transaction, Generic Health will gain access to over 60 registered products having sales of over Australian dollar 30 million

    Read More
  • Lupin launches Tavaborole Topical Solution
    13th Jul 2021, 15:22 PM

    The product will be manufactured at Lupin’s facility in Pithampur, India

    Read More

Source: www.accordfintech.com | DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.